- Jun 11, 2026
- 2403219710
MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
GET PAID FOR SHOPPING AT ALL YOUR FAVORITE STORES!
Sound too good to be true? Here’s the deal: Stores pay us a commission for sending you their way. We share that with you as Cash Back. Everyone wins!
.png)
